QYUNS THERAPEUTICS CO., LTD. / 江蘇荃信生物醫藥股份有限公司 ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated 12 March 2024 (the "**Prospectus**") issued by Qyuns Therapeutics Co., Ltd. (the "**Company**").

Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information			
Stock code	2509		
Stock short name	QYUNS-B		
Dealings commencement date	20 March 2024*		

**see note at the end of the announcement*

Price Inform	nation
Final Offer Price	HK\$19.800
Offer Price Range	HK\$19.800 - HK\$20.200
Offer Price Adjustment exercised	No

Offer Shares and Share Capital				
Number of Offer Shares	12,046,400			
Number of Offer Shares in Public Offer (after reallocation)	2,140,800			
Number of offer shares in International Offer (after	9,905,600			
reallocation)				
Number of issued shares upon Listing	222,071,600			

The number of offer shares above is determined after taking into account the additional shares issued under the following Offer Size Adjustment Option

Offer Size Adjustment Option (Upsize option)				
Number of additional shares issued under the option	-			
- Public Offer	-			
- International Offer	-			

Over-al	location

_

No. of Offer Shares over-allocated

Proceeds				
Gross proceeds (Note)	HK\$ 238.52 million			
Less: Estimated listing expenses payable based on Final	HK\$ (75.25) million			
Offer Price				
Net proceeds	HK\$ 163.27 million			
Net proceeds	HK\$ 163.27 million			

Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	14,525
No. of successful applications	4,237
Subscription level	163.15 times
Re-allocation	Yes
No. of Offer Shares initially available under the Hong Kong Public	1,204,800
Offering	
No. of Offer Shares reallocated from the International Offering	936,000
Final no. of Offer Shares under the Public Offer (after	2,140,800
reallocation)	
% of Offer Shares under the Hong Kong Public Offering to the	17.77%
Global Offering	

Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to <u>https://www.hkeipo.hk/iporesult</u> to perform a search by name or identification number or <u>https://www.hkeipo.hk/iporesult</u> for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	109
Subscription Level	0.9965 times
No. of Offer Shares initially available under the International	10,841,600
Offering	
No. of Offer Shares reallocated to the Hong Kong Public Offering	936,000
Final no. of Offer Shares under the International Offering (after	9,905,600
reallocation)	
% of Offer Shares under the International Offering to the Global	82.23%
Offering	

The Directors confirm that, to the best of their knowledge and save as the waiver and consent granted by the Stock Exchange, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, existing shareholders, substantial shareholders, existing shareholders, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, substantial shareholders, substantial shareholders, existing shareholders, any of the Company, controlling shareholders, substantial shareholders, existing shareholders, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investors

Investor	No. of Offer Shares allocated	% of Offer Shares	% of total issued H Shares after the Global Offering	% of total issued share capital after the Global Offering	Existing shareholders or their close associates
Huadong					
Medicine					
Investment					
Holding (Hong					
Kong) Limited	1,976,800	16.41%	0.97%	0.89%	Yes
Beevest Capital					
Limited	1,976,800	16.41%	0.97%	0.89%	No
JianXin Medical					
Technology					
Limited	5,930,400	49.23%	2.90%	2.67%	Yes
Total	9,884,000	82.05%	4.83%	4.45%	

Allottees with waivers/consents obtained

Investor	No. of shares allocated	% of offer shares	% of total issued H Shares after the Global Offering	% of total issued share capital after the Global Offering	Relationship*
					core connected
Huadong					person and
Medicine					existing
Investment					shareholder or
Holding (Hong					its close
Kong) Limited	1,976,800	16.41%	0.97%	0.89%	associate
					core connected
					person and
					existing
JianXin Medical					shareholder or
Technology					its close
Limited	5,930,400	49.23%	2.90%	2.67%	associate
Total	7,907,200	65.64%	3.86%	3.56%	

[#]The H Shares placed to the above allottees are in compliance with all the conditions under the consent granted by the Stock Exchange.

*The Company has applied for, and the Stock Exchange has approved, a waiver from strict compliance with Main Board Rule 9.09(b) and 10.04 of the Listing Rules. Please refer to the "Waivers from Strict Compliance with the Requirements Under the Listing Rules and Exemption from the Companies (Winding Up and Miscellaneous Provisions) Ordinance" section in the Company's Prospectus for further details.

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Qiu Jiwan / 裘霽宛	10,000,000			19 March
(" Mr. Qiu ") Note 2	(Unlisted Shares)	N/A	4.50%	2025 Note 1
Hangzhou Quanyi				
Investment				
Management				
Partnership (General				
Partnership) / 杭州荃				
毅投資管理合夥企業				
(普通合夥)				
("Hangzhou	40,000,000 (H			19 March
Quanyi") Note 2	Shares)	19.54%	18.01%	2025 Note 1
Yu Guo'an (余國安)	40,000,000 (H			19 March
(" Mr. Yu ") ^{Note 2}	Shares)	19.54%	18.01%	2025
Shanghai Quanyou				
Fanyue Investment				
Management				
Partnership (Limited				
Partnership) / 上海荃				
友凡悅投資管理合夥				
企業(有限合夥)				
("Shanghai	5,000,000 (H			19 March
Quanyou") Note 2	Shares)	2.44%	2.25%	2025 Note 1
Taizhou Xinfu				
Tongxin Enterprise				
Management				
Partnership (Limited				
Partnership) / 泰州信				
孚同心企業管理合夥				
企業(有限合夥)				
("Xinfu Tongxin") Note 2	15,550,000 (H		- 000	19 March
	Shares)	7.59%	7.00%	2025 Note 1
Subtotal Note 3	70,550,000	29.57%	31.77%	

Notes:

- (1) The expiry date of the lock-up period shown in the table above is pursuant to the Hong Kong Underwriting Agreement and PRC Company Law.
- (2) Hangzhou Quanyi is owned as to 50% by Mr. Qiu and 50% by Mr. Yu, both being its general partners acting in concert pursuant to the supplemental partnership agreement of Hangzhou Quanyi. For details, see "Relationship with Our Controlling Shareholders—Overview" in the Prospectus. By virtue of the SFO, each of Mr. Qiu and Mr. Yu is deemed to be interested in the Shares held by Hangzhou Quanyi. Mr. Qiu is the general partner who holds approximately 7.20% interest in Xinfu Tongxin. By virtue of the SFO, Mr. Qiu is deemed to be interested in the Shares held by Xinfu Tongxin. Mr. Qiu is the general partner who holds approximately 45.71% interest in Shanghai Quanyou. Shanghai Quanyou holds 5,000,000 Shares, representing approximately 2.38% and 2.25% of our Shares in issue immediately prior to and following the

Namo	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Name completion of th	upon listing	undertakings upon listing tue of the SFO, Mr. Qiu is	listing	undertakings
			es, representing approxin	

Pre-IPO Investors (as defined in the "History and Corporate Structure" section of the Prospectus)

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Gongqingcheng Triwise Kangxin	3,899,800 (H Shares)	1.90%	1.76%	19 March 2025
Venture Capital	Shares			2025
Partnership (Limited				
Partnership) / 共青城				
勤智康鑫創業投資				
合夥企業(有限合夥)				
("Gongqingcheng				
Triwise Kangxin")				
Triwise Huisheng	595,400 (H	0.29%	0.27%	19 March
Venture Capital	Shares)			2025
Partnership (Limited				
Partnership) / 共青城				
勤智慧升創業投資				
合夥企業(有限合夥)				
("Triwise				
Huisheng")				
Shenzhen Lucky-	3,230,000 (H	1.58%	1.45%	19 March
source III Venture	Shares)			2025
Capital Center				
(Limited Partnership) / 深圳瑞享源三號創				
業投資中心(有限合				
夥) ("Lucky-source				
III")				
Shenzhen Lucky-	4,500,000 (H	2.20%	2.03%	19 March
source IV Venture	Shares)			2025
Capital Center				
(Limited Partnership) / 深圳瑞享源肆號創				

	Number of shares held in the Company subject to lock-up undertakings	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon	% of shareholding in the Company subject to lock-up undertakings upon	Last day subject to the lock-up
Name	upon listing	listing	listing	undertakings
業投資中心(有限合				
夥) ("Lucky-source				
IV")				
Suzhou Guanhong	6,540,000 (H	3.19%	2.94%	19 March
Venture Capital	Shares)			2025
Center (Limited Partnership) / 蘇州冠				
-				
鴻創業投資中心(有				
限合夥) ("Suzhou				
Guanhong")	5 000 000 (II	2 4 4 0/	2.250/	10 Maush
Shanghai Shuochen Investment	5,000,000 (H	2.44%	2.25%	19 March 2025
Management Co.,	Shares)			2023
Ltd. / 上海碩臣投資				
管理有限公司				
("Shanghai				
Shuochen")				
Jiaxing Jiquan Equity	3,572,400	N/A	1.61%	19 March
Investment	(Unlisted Shares)			2025
Partnership (Limited				
Partnership) / 嘉興集				
荃股權投資合夥企				
業(有限合夥)				
("Jiaxing Jiquan")				
Shenzhen Qianhai	3,500,000 (H	1.71%	1.58%	19 March
Efung Taihe Equity	Shares)			2025
Investment Fund				
Enterprise (Limited				
Partnership) / 深圳市				
前海倚鋒太和股權				
投資基金企業(有限				
合夥) ("Qianhai				
Efung")				
Shenzhen Kaitian	2,977,000 (H	1.45%	1.34%	19 March
Yunqi Venture	Shares)			2025
Capital Center (Limited Partnership)				
/ 深圳開天雲起創業				
投資中心(有限合夥)				
("Shenzhen				
Kaitian")				
TWVC Panglin	2,500,600 (H	1.22%	1.13%	19 March
Qyuns Investment	Shares)	/0		2025
Limited ("TWVC				

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Panglin")				
Nanjing Yuzhihua	2,000,000 (H	0.98%	0.90%	19 March
Pharmaceutical	Shares)			2025
Technology				
Partnership (Limited				
Partnership) / 南京裕				
之華醫藥科技合夥				
企業 (有限合夥)				
("Nanjing Yuzhihua")				
Xinyu Tongchuang	1,450,000 (H	0.71%	0.65%	19 March
Guosheng Science	Shares)			2025
and Innovation				
Industry Investment				
Partnership (Limited Partnership) / 新余市				
同創國盛科創產業				
合夥) ("Cowin				
Guosheng") Gongqingcheng	1,250,000 (H	0.61%	0.56%	19 March
Jiayin Lucky-source	1,230,000 (H Shares)	0.01%	0.30%	2025
Equity Investment	Sharesy			2023
Partnership (Limited				
Partnership) / 共青城				
佳銀瑞享源股權投				
資合夥企業(有限合				
夥) ("Jiayin Lucky-				
source")				
Shenzhen Yuanzhi	730,000 (H	0.36%	0.33%	19 March
Fuhai New Industry II	Shares)			2025
Investment Enterprise				
(Limited Partnership)				
/ 深圳遠致富海新興				
產業二期投資企業				
(有限合夥) ("Yuanzhi Fuhai")				
Everest No. 37	730,000 (H	0.36%	0.33%	19 March
(Shenzhen) Venture	Shares)	0.5070	0.5570	2025
Capital Center				
(Limited Partnership)				
/ 朗瑪三十七號(深				
圳) 創業投資中心(有				

限合夥) ("Everest No. 37)" Manjing Talent Innovation Venture Capital Fund Partnership (Limited Partnership) / 南京市 人才創新創業投資 基金合夥企業(有限 合夥) ("Nanjing Talent") Hangzhou Zhongmei Huadong Shares) Atta / 杭州中美華東 製案有限公司 ("Zhongmei Huadong") Taizhou Hongtai Heath Investment Shares) Management Center (Limited Partnership) /泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health") Taizhou Jianxin Venture Capital Co., Lid. / 杭州中美華東 Darta Shares) Management Center (Limited Partnership) /泰州洪泰健康投資 管理中心(有限合夥) ("Taizhou Jianxin Venture Capital Co., Lid. / 添州健禽創業 投資有限公司 ("Taizhou Jianxin") Taizhou Jianxin ("Taizhou Jianxin") Taizhou Jianxin ("Taizhou Jianxin") Taizhou Jianxin ("Taizhou Jianxin") Taizhou Jianxin ("Taizhou Jianxin") Taizhou China Medical City Rongjianda Venture Capital Co., Lid. /泰 Hung 國家政副社 基金合夥(Hung Shares) Taizhou China ("Taizhou Jianxin") Shares) Taizhou China ("Taizhou Jianxin") Shares) Taizhou China ("Taizhou Jianxin") Shares) Taizhou China ("Taizhou Jianxin") Shares) Taizhou China ("Taizhou Jianxin") Shares) Taizhou China Matrik Partners China 9,853,116 (H 4,81% A,43% (19 March 2025 Nanjing Tongren Bota Equity Newsiment Center (Thorgai Tongren Bota Equity Newsiment Center (Capital Co., Lat. /泰 Nanjing Tongren Bota Equity Newsiment Center	Name	Number of shares held in the Company subject to lock-up undertakings	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon	% of shareholding in the Company subject to lock-up undertakings upon	Last day subject to the lock-up
No. 37")		upon listing	listing	listing	undertakings
Nanjing Talent Innovation Venture Capital Fund Partnership (Limited Partnership) 前京市 人才創新創業投資 基金合移企業(有限 合夥) ("Nanjing Talent")0.28%19 March 2025Mangzhou Zhongmei Hangzhou Zhongmei Huadong Pharmaceutical Co., Lud. /杭州中美華東35,900,000 (H Shares)17.53%16.17%19 March 2025Mangzhou Zhongmei Huadong Pharmaceutical Co., Lud. /杭州中美華東35,900,000 (H Shares)17.53%16.17%19 March 2025Taizhou Zhongmei Huadong") Taizhou Hongtai Heath Investment (Limited Partnership) /泰州洪泰健康投資 管理中心/衣服合影)18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Jianxin ("Hongtai Health")18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Jianxin ("Faizhou Jianxin")7,500,000 (including Shares)1.83%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 H Shares)3.66%3.38%19 March 2025Taizhou China Medical City Rongjianda Venture Capital Co., Ltd. / & Mire Shares)3.06%3.38%19 March 2025Taizhou China ("Taizhou Ginad")7,500,000 H Shares)3.66%3.38%19 March 2025Taizhou China Medical City Rongjianda Venture Capital Co., Ltd. / & Mire Shares)4.81%4.44%19 March 2025Matrix Partners China Orgen Andrig Torgen Heading")4.375,000 (H Shares)2.14%1.97%19 March 2025Matrix Partners China Boda Equity Nota Equity Shares)2.14%1.97%19 March 2					
Innovation Venture Capital Fund Partnership (Limited Partnership / 南京市 人才創新創業投資 基金合夥企業(有限 合夥) (*Nanjing Talent*) Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. /杭州中美華東 製藥有限公司 Taizhou Hongtai Health Investment Management Center (Limited Partnership) /泰州洪泰健康投資 管理中心(有限合夥) (*Hongtai Health*) Taizhou Jianxin Taizhou Jianxin (*Taizhou Jianxin*) Taizhou Jianxin (*Taizhou Jianxin*) Taizhou Jianxin (*Taizhou Jianxin*) Taizhou Jianxin (*Taizhou Jianxin*) Taizhou Jianxin (*Taizhou Jianxin*) Taizhou Jianxin (*Taizhou Jianxin*) Management Center (Limited Partnership) /泰州洪泰健康投資 管理中心(有限合夥) (*Hongtai Health*) Taizhou Jianxin (*Taizhou Jianxin*) Taizhou China Madia Yenure Capital Co., Ltd. /泰 州中國醫業城融健 達創業投資有限公司 Taizhou Shares and 3,750,000 (H Shares) Taizhou China Matrix Partners China Matrix Partner China Matrix Partners China Matrix		625 000 (H	0.210/	0.280/	10 March
Capital Fund Partnership (Limited Partnership) / 南京市 人才創新創業投資 基金合彩企業(有限 合彩) ("Nanjing Talent")Image: Capital Co., Shares)Image: Capital Co., Shares) <thimage: capital="" co.,<b<="" td=""><td></td><td>, ,</td><td>0.31%</td><td>0.28%</td><td></td></thimage:>		, ,	0.31%	0.28%	
Partnership (Limited Partnership) / 南京市 人才創新創業投資 基金合彩企業(有限 合彩) ("Nanjing Talent")35,900,000 (H Shares)17.53%16.17%19 March 2025Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. / 杭州中美華東 製薬有限公司 ("Zhongmei Huadong")35,900,000 (H Shares)17.53%16.17%19 March 2025Yamaceutical Co., Ltd. / 杭州中美華東 製薬有限公司 ("Zhongmei Huadong")18,750,000 (H Shares)9.16%8.44%19 March 2025Yaizhou Hongtai Health Investment Management Center (Limited Partnership)18,750,000 (H Shares)9.16%8.44%19 March 2025Yaizhou Jianxin ("Hongtai Health")7,500,000 Shares)1.83%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 Shares)1.83%3.38%19 March 2025Taizhou China Medical City Rongianda 'Venture Capital Co., Ltd. /秦 M'H 國醫藥以融健 達創業投資有限公司 ("Tongianda")7,500,000 H Shares)3.66% Shares)3.38%19 March 2025Taizhou China Medical City Rongianda 'N7,500,000 H Shares)3.66%3.38%19 March 2025Taizhou China Medical City Rongianda 'N9,853,116 (H Shares)4.81%4.44%19 March 2025Matrix Partners China Boda Equity Boda Equity Investment Center9,853,116 (H Shares)2.14%1.97%19 March 2025		Shares			2023
Partnership)/南京市 人才創新創業投資 基金合夥企業(有限 合夥)("Nanjing Talent")Image (Construction)Image (Construction)Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. / 杭州中美華東 製藥有限公司 ("Zhongmei Huadong")35,900,000 (H Shares)17.53%16.17%19 March 2025Taizhou Huadong")18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Hongtai Health Investment Management Center (Limited Partnership) / 漆州洪泰健康投資 管理中心(有限合夥)18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 (including Unlisted Shares and 3,750,000 H Shares)1.83%3.38%19 March 2025Taizhou Jianxin" ("Taizhou Jianxin")7,500,000 Shares)1.83%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Shares)9,853,116 (H Shares)4.81%4.44%19 March 2025Nanjing Tongren Boda Equity Lovestment Center9,853,116 (H Shares)2.14%1.97%2	-				
시オ創新創業投資 基金合彩企業(有限 合彩) ("Nanjing Tatent")35,900,000 (H Shares)17.53%16.17%19 March 2025Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. /杭州中美華東 製藥有限公司 ("Zhongmei Huadong")35,900,000 (H Shares)17.53%16.17%19 March 2025Taizhou Hongtai Health Investment Management Center (Limited Partnership) /泰州洪泰健康投資 管理中心(有限合彩) ("Hongtai Health")18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Jianxin ("Hongtai Health")7,500,000 (including 3,750,0001.83%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 Shares)1.83%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")9,853,116 (H Shares)4.81%4.44%19 March 2025Martix Partners China Oda Equity Nu L.P.9,853,116 (H Shares)2.14%1.97%19 March 2025Nanjing Tongren Boda Equity Investment Center4,375,000 (H Shares)2.14%1.97%19 March 2025	± ·				
基金合夥企業(有限 合夥) ("Nanjing Talent") Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. / 杭州中美華東 製藥有限公司 ("Zhongmei Huadong") Taizhou Hongtai Health Investment Management Center (Limited Partnership) /泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health") Taizhou Jianxin Taizhou Jianxin Taizhou Jianxin ("Taizhou Jianxin Taizhou Jianxin Taizhou Jianxin Taizhou Jianxin Taizhou Jianxin Taizhou Jianxin ("Taizhou Jianxin Taizhou Jianxin ("Taizhou Jianxin Taizhou Jianxin ("Taizhou Jianxin ("Taizh	=				
合夥) ("Nanjing Talent")35,900,000 (H Shares)17.53%16.17%19 March 2025Hangazhou Zhongmei Huadong Pharmaceutical Co., Ltd. / 杭州中美華東 製藥有限公司 ("Zhongnei Huadong")35,900,000 (H Shares)17.53%16.17%19 March 2025Taizhou Hongtai Health Investment Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Jianxin Venture Capital Co., Ltd. / 泰州健鑫創業 投資有限公司 ("Taizhou Jianxin")7,500,000 (including 3,750,0001.83%3.38%19 March 2025Taizhou Jianxin Venture Capital Co., Ltd. / 泰州健鑫創業 投資有限公司 ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Toigianda")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Shares)9,853,116 (H Shares)4.81%4.44%19 March 2025Taijing Tongren Boda Equity Investment Center9,853,116 (H Shares)2.14%1.97%19 March 2025					
Talent")Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. / 杭州中美華東 製藥有限公司 ("Zhongmei Huadong")35,900,000 (H Shares)17.53%16.17%19 March 2025Mangemei Huadong")201Taizhou Hongtai Health Investment Management Center (Limited Partnership)18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Hongtai ("Hongtai Health Investment Management Center (Limited Partnership)18,750,000 (H Shares)9.16%8.44%19 March 2025Yaght Health") Taizhou Jianxin7,500,000 (including and 3,750,0001.83%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China Rongijanda Venture Capital Co., Ltd. /泰 M中重醫藥城融健 達創業投資有限公 congijanda Venture Capital Co., Ltd. /泰 Mmedisäti Grames7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China Rongjianda Venture Capital Co., Ltd. /泰 Mmedisätigt E E Alming Tongren9,853,116 (H Shares)4.81% 2.14%4.44%19 March 2025Marijig Tongren Boda Equity Investment Center9,853,116 (H Shares)2.14%1.97%19 March 2025Nanjig Tongren Boda Equity Investment Center9,853,000 (H Shares)2.14%1.97					
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. /杭州中美華東 製藥有限公司 ("Zhongmei Huadong")35,900,000 (H Shares)17.53%16.17%19 March 2025Waga fi Ry Col ("Zhongmei Huadong")Shares)916.17%19 March 2025Taizhou Hongtai Health Investment 					
Huadong Pharmaceutical Co., Ltd. / 杭州中美華東 製藥有限公司 ("Zhongmei Huadong")Shares)2025Taizhou Hongtai Health Investment Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")18,750,000 (H Shares)9.16%8.44%19 March 2025Taizhou Jianxin ("Hongtai Health")7,500,000 (including 3,750,0001.83%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 (including 3,750,000 H Shares)1.83%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 H Shares)3.66%3.38%19 March 2025Taizhou Jianxin ("Taizhou Jianxin")7,500,000 H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China ("Taizhou Shares)9,853,116 (H Shares)4.81%4.44%19 March 2025Matrix Partners China Oda Equity Investment Center9,853,116 (H Shares)2.14%1.97%19 March 2025Manjing Tongren Boda Equity Investment CenterShares)2.14%1.97%19 March 2025	/	25 000 000 (II	17 520/	16 170/	10 March
Pharmaceutical Co., Ltd. / 杭州中美華東 製藥有限公司 ("Zhongmei Huadong")Image: Constraint of the second	0		17.35%	10.17%	
Ltd. /杭州中美華東 製藥有限公司 ("Zhongmei Huadong")I8,750,000 (H 9.16%9.16%8.44%19 March 2025Taizhou Hongtai Health Investment Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")18,750,0008.44%19 March 2025("Hongtai Health") Taizhou Jianxin ("Hangtai Health")7,500,0001.83%3.38%19 March 2025("Hangtai Health") Taizhou Jianxin ("Taizhou Jianxin ("Taizhou Jianxin")7,500,0001.83%3.38%19 March 2025Ltd. /泰州健鑫創業 投資有限公司 ("Taizhou Jianxin")7,500,000 (H Shares)3.66%3.38%19 March 2025Taizhou China Medical City Rongjianda Venture Capital Co., Ltd. /泰 M中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")9,853,116 (H Shares)4.81%4.44%19 March 2025Matrix Partners China VI, L.P.9,853,116 (H Shares)4.81%4.44%19 March 2025Nanjing Tongren Hoda Equity Investment Center9,853,116 (H Shares)2.14%1.97%19 March 2025	0	Shares)			2023
製藥有限公司 ("Zhongmei Huadong") Taizhou Hongtai 18,750,000 (H 9.16% 8.44% 19 March Health Investment Shares) Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health") Taizhou Jianxin 7,500,000 1.83% 3.38% 19 March Venture Capital Co., (including Ltd. / 泰州健鑫創業 3,750,000 投資有限公司 Unlisted Shares and 3,750,000 H Shares) Taizhou Jianxin") Taizhou Jianxin") Taizhou Jianxin ("Taizhou Jianxin") Taizhou Jianxin") Taizhou Jianxin") Taizhou Jianxin") Taizhou Jianxin" ("Taizhou Jianxin") Taizhou Jianxin") Taizhou Jianxin") Taizhou Linia ("Taizhou Jianxin") Taizhou Jianxin" Taizhou Jianxin") Taizhou Jianxin" Taizhou Jianxin") Taizhou Jianxin" Taizhou Jianxin Taixin Taizhou Jianxin" Taizhou Jian	-				
("Zhongmei Huadong")18,750,000 (H9.16%8.44%19 MarchTaizhou Hongtai Health Investment Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")9.16%8.44%19 March/ 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")					
Huadong")Taizhou Hongtai18,750,000 (H9.16%8.44%19 MarchHealth InvestmentShares)2025Management Center2025(Limited Partnership)/2025/ 泰州洪泰健康投資 </td <td></td> <td></td> <td></td> <td></td> <td></td>					
Taizhou Hongtai Health Investment Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")18,750,000 (H Shares)9.16%8.44%19 March 2025管理中心(有限合夥) ("Hongtai Health")	. <u> </u>				
Health Investment Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")Shares)2025("Hongtai Health")		18 750 000 (H	9.16%	8 44%	19 March
Management Center (Limited Partnership) / 泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")····Taizhou Jianxin7,500,0001.83%3.38%19 MarchTaizhou Jianxin7,500,0001.83%3.38%2025Ltd. / 泰州健鑫創業 投資有限公司 ("Taizhou Jianxin")3,750,00020252025Taizhou Jianxin")Unlisted Shares and 3,750,000 H3.66%3.38%19 MarchTaizhou China Medical City Capital Co., Ltd. / 泰 州中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")7,500,000 (H3.66%3.38%19 MarchMatrix Partners China VI, L.P.9,853,116 (H4.81%4.44%19 MarchMatrix Partners China VI, L.P.9,853,116 (H2.14%1.97%2025Nanjing Tongren Boda Equity Investment Center4,375,000 (H2.14%1.97%19 March	-	, , , ,	9.1070	0.11/0	
(Limited Partnership) /泰州洪泰健康投資 管理中心(有限合夥) ("Hongtai Health")지(1)Taizhou Jianxin7,500,0001.83%3.38%19 MarchVenture Capital Co., Venture Capital Co., Ltd. /泰州健鑫創業 改資有限公司 ("Taizhou Jianxin")7,500,0001.83%3.38%19 MarchW資資有限公司 Congianda Venture Capital Co., Ltd. /泰 州中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")7,500,000 (H3.66%3.38%19 MarchMatrix Partners China Of (Rongianda")9,853,116 (H4.81%4.44%19 MarchMatrix Partners China Doda Equity9,853,116 (H2.14%1.97%2025Nanjing Tongren Boda Equity4,375,000 (H2.14%1.97%2025		21141 (S)			
管理中心(有限合夥) ("Hongtai Health")Taizhou Jianxin7,500,0001.83%3.38%19 MarchTaizhou Jianxin(including (including 2025)20252025Ltd. /泰州健鑫創業3,750,00020252025投資有限公司 ("Taizhou Jianxin")Unlisted Shares and 3,750,000 H Shares)13.66%3.38%19 March 2025Taizhou China Medical City Capital Co., Ltd. /泰 州中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")7,500,000 (H Shares)3.66%3.38%19 March 2025Matrix Partners China VI, L.P.9,853,116 (H Shares)4.81%4.44%19 March 2025Nanjing Tongren Boda Equity4,375,000 (H Shares)2.14%1.97%19 March 2025Nanjing Tongren Boda Equity4,375,000 (H Shares)2.14%1.97%19 March 2025	0				
("Hongtai Health")Taizhou Jianxin7,500,0001.83%3.38%19 MarchVenture Capital Co., Ltd. / 泰州健鑫創業3,750,00020252025Ltd. / 泰州健鑫創業3,750,000 H20252025化"Taizhou Jianxin")and 3,750,000 H40000 H2025Taizhou China7,500,000 (H3.66%3.38%19 MarchMedical CityShares)202520252025Rongjianda Venture520252025Capital Co., Ltd. / 泰442025M中國醫藥城融健4.44%4.44%19 March達創業投資有限公9,853,116 (H4.81%4.44%VI, L.P.Shares)2025Nanjing Tongren4,375,000 (H2.14%1.97%Boda EquityShares)2.14%1.97%Investment Center662025	/ 泰州洪泰健康投資				
("Hongtai Health")Taizhou Jianxin7,500,0001.83%3.38%19 MarchVenture Capital Co., Ltd. / 泰州健鑫創業3,750,00020252025Ltd. / 泰州健鑫創業3,750,000 H20252025化"Taizhou Jianxin")and 3,750,000 H40000 H2025Taizhou China7,500,000 (H3.66%3.38%19 MarchMedical CityShares)202520252025Rongjianda Venture520252025Capital Co., Ltd. / 泰442025M中國醫藥城融健4.44%4.44%19 March達創業投資有限公9,853,116 (H4.81%4.44%VI, L.P.Shares)2025Nanjing Tongren4,375,000 (H2.14%1.97%Boda EquityShares)2.14%1.97%Investment Center662025	管理中心(有限合夥)				
Taizhou Jianxin7,500,0001.83%3.38%19 March 2025Venture Capital Co., Ltd. / 泰州健鑫創業 投資有限公司 ("Taizhou Jianxin")(including 3,750,000 H Shares)20252025Taizhou Jianxin")Unlisted Shares and 3,750,000 H Shares)and 3,750,000 H Shares)2025Taizhou China Medical City Capital Co., Ltd. / 泰 M中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")7,500,000 (H Shares)3.66%3.38%19 March 2025Matrix Partners China VI, L.P.9,853,116 (H Shares)4.81%4.44%19 March 2025Nanjing Tongren Boda Equity Investment Center4,375,000 (H Shares)2.14%1.97%19 March 2025					
Ltd. / 泰州健鑫創業 投資有限公司 ("Taizhou Jianxin") 3,750,000 Unlisted Shares and 3,750,000 H Shares)	Taizhou Jianxin	7,500,000	1.83%	3.38%	19 March
投資有限公司 ("Taizhou Jianxin")Unlisted Shares and 3,750,000 H Shares)Image: Constant of the state of the	Venture Capital Co.,	(including			2025
AC (Taizhou Jianxin'')and 3,750,000 H Shares)and 3,750,000 H Shares)Taizhou China7,500,000 (H Shares)3.66%3.38%Medical CityShares)2025Rongjianda Venture Capital Co., Ltd. /泰 州中國醫藥城融健	Ltd. / 泰州健鑫創業				
Taizhou Jianxin)Shares)Taizhou China7,500,000 (HMedical CityShares)Rongjianda VentureShares)Capital Co., Ltd. /泰	投資有限公司				
Taizhou China7,500,000 (H3.66%3.38%19 MarchMedical CityShares)2025Rongjianda Venture2025Capital Co., Ltd. /泰//泰-州中國醫藥城融健-達創業投資有限公-司 ("Rongjianda")-Matrix Partners China9,853,116 (HVI, L.P.Shares)Nanjing Tongren4,375,000 (HBoda EquityShares)Investment Center-	("Taizhou Jianxin")				
Medical City Rongjianda Venture Capital Co., Ltd. /泰 州中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")Shares)2025Matrix Partners China VI, L.P.9,853,116 (H Shares)4.81%4.44%19 March 2025Nanjing Tongren Boda Equity Investment Center4,375,000 (H Shares)2.14%1.97%19 March 2025	Taishay Ohim		0 ((0)	2 200/	
Rongjianda Venture Capital Co., Ltd. / 泰 州中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")Image: Constant of the second se			3.00%	3.38%	
Capital Co., Ltd. / 泰 州中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")Letter Letter	2	Shares)			2023
州中國醫藥城融健 達創業投資有限公 司 ("Rongjianda")LenLenLen初 ("Rongjianda")9,853,116 (H4.81%4.44%19 MarchVI, L.P.9,853,116 (H4.81%2025Nanjing Tongren4,375,000 (H2.14%1.97%19 MarchBoda EquityShares)20252025Investment Center2025	65				
達創業投資有限公 司 ("Rongjianda") </td <td>· · ·</td> <td></td> <td></td> <td></td> <td></td>	· · ·				
司 ("Rongjianda") </td <td></td> <td></td> <td></td> <td></td> <td></td>					
Matrix Partners China9,853,116 (H4.81%4.44%19 MarchVI, L.P.Shares)2025Nanjing Tongren4,375,000 (H2.14%1.97%19 MarchBoda EquityShares)2025Investment Center2025					
VI, L.P.Shares)2025Nanjing Tongren4,375,000 (H2.14%1.97%19 MarchBoda EquityShares)20252025Investment Center2025		0.070.111.77			
Nanjing Tongren4,375,000 (H2.14%1.97%19 MarchBoda EquityShares)2025Investment Center			4.81%	4.44%	
Boda EquityShares)2025Investment Center		/	0 1 40/	1.070/	
Investment Center	000		2.14%	1.9/%	
	1 1	Shares)			2025
	(Limited Partnership)				

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
/ 南京同人博達股權				
投資中心(有限合夥)				
("Tongren Boda")				
Suzhou Hefu Ruitai	3,750,000 (H	1.83%	1.69%	19 March
Equity Investment	Shares)			2025
Center (Limited				
Partnership) / 蘇州合				
富瑞泰股權投資中				
心(有限合夥) ("Hefu				
Ruitai")				
Shenzhen Triwise	1,250,000 (H	0.61%	0.56%	19 March
Rozman Phase II	Shares)			2025
Investment				
Partnership (Limited				
Partnership) / 深圳勤				
智羅茲曼二期投資				
合夥企業(有限合夥)				
("Triwise Rozman")				
Shenzhen Triwise	1,250,000 (H	0.61%	0.56%	19 March
Kangxin Venture	Shares)			2025
Capital Partnership				
(Limited Partnership)				
/ 深圳勤智康信創業				
投資合夥企業(有限				
合夥) ("Shenzhen				
Triwise Kangxin")				
Shenzhen Triwise	730,000 (H	0.36%	0.33%	19 March
Detai New	Shares)			2025
Technology Venture				
Capital Enterprise				
(Limited Partnership)				
/ 深圳勤智德泰新科				
技創業投資企業(有				
限合夥) ("Triwise				
Detai")		A =-		10
Matrix Partners China	1,066,884 (H	0.52%	0.48%	19 March
VI-A, L.P.	Shares)	(0.070/	<u> </u>	2025
Subtotal	135,025,200	62.37%	60.80%	

The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

Existing Shareholders (other than the Pre-IPO Investors as defined in the "History and Corporate Structure" section of the Prospectus)

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Li Jianwei / 李建偉	1,450,000 (H	0.71%	0.65%	19 March
	Shares)			2025
Qiu Zhihua / 裘之華	1,000,000 (H	0.49%	0.45%	19 March
	Shares)			2025
Guo Xinjun / 郭新軍	500,000 (H	0.24%	0.23%	19 March
·	Shares)			2025
Yu Guoliang / 余國良	1,500,000 (H	0.73%	0.68%	19 March
	Shares)			2025
Subtotal	4,450,000	2.17%	2.00%	

The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

Cornerstone Investors

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H- shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Beevest Capital	1,976,800 (H	0.97%	0.89%	19 September
Limited	Shares)			2024
JianXin Medical	5,930,400 (H	2.90%	2.67%	19 September
Technology Limited / 健鑫醫藥科技有限公 司	Shares)			2024
Huadong Medicine Investment Holding (Hong Kong) Limited / 華東醫藥投資控股 (香港)有限公司	1,976,800 (H Shares)	0.97%	0.89%	19 September 2024
Subtotal	9,884,000	4.83%	4.45%	

The Cornerstone Investors shall not dispose of any of the Offer Shares subscribed pursuant to the cornerstone investment agreements on or before the indicated date.

Placees ⁽¹⁾	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing ⁽²⁾	% of total issued share capital upon Listing
Top 1	5,930,400	59.87%	49.23%	20,930,400	9.43%
Top 5	9,884,800	99.79%	82.06%	60,784,800	27.37%
Top 10	9,885,800	99.80%	82.06%	60,785,800	27.37%
Top 25	9,888,800	99.83%	82.09%	60,788,800	27.37%

Notes

(1) Ranking of placees is based on the number of H Shares allotted to the placees.

(2) Number of shares held upon listing includes existing shares.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders ⁽¹⁾	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing	
Top 1	0	0.00%	0.00%	60,550,000	29.57%	70,550,000
Top 5	7,907,200	79.83%	65.64%	145,277,200	70.95%	159,027,200
Top 10	7,907,200	79.83%	65.64%	180,397,400	88.11%	194,147,400
Top 25	9,891,200	99.78% ⁽²⁾	82.11%	202,594,000	98.95%	216,344,000

Notes

(1) Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

(2) The number of allocation for 1 Hong Kong Public Offering investor is deducted from the number of H shares allotted to align with the description of subtitle of this column.

(3) Number of shares held upon listing includes existing shares.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders ⁽¹⁾	Number of H Shares allotte d	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing ⁽²⁾	% of total issued share capital upon Listing
Top 1	0	0.00%	0.00%	70,550,000	31.77%
Top 5	7,907,200	79.83%	65.64%	159,027,200	71.61%
Top 10	7,907,200	79.83%	65.64%	194,147,400	87.43%
Top 25	9,884,000	99.78%	82.05%	219,909,200	99.03%

Notes

(1) Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

(2) Number of shares held upon listing includes existing shares.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

Pool A:

			APPROXIMAT
			PERCENTAGE ALLOTTE
NO. OF H SHARES APPLIED	NO. OF VALID		OF THE TOTAL NO. OF
FOR	APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	SHARES APPLIED FO
200	4,099	205 out of 4,099 applicants to receive 200 H Shares	5.009
400	2,128	192 out of 2,128 applicants to receive	5.007
400	2,120	200 H Shares	4.519
600	481	58 out of 481 applicants to receive	
		200 H Shares	4.029
800	277	39 out of 277 applicants to receive	
		200 H Shares	3.52
1,000	467	73 out of 467 applicants to receive	
		200 H Shares	3.13
1,200	141	24 out of 141 applicants to receive	
		200 H Shares	2.84
1,400	110	21 out of 110 applicants to receive	
		200 H Shares	2.73
1,600	107	22 out of 107 applicants to receive	
		200 H Shares	2.57
1,800	74	16 out of 74 applicants to receive 200	
		H Shares	2.40
2,000	2,289	527 out of 2,289 applicants to receive	
		200 H Shares	2.30
3,000	313	99 out of 313 applicants to receive	
		200 H Shares	2.11
4,000	757	269 out of 757 applicants to receive	
		200 H Shares	1.78
5,000	244	101 out of 244 applicants to receive	
		200 H Shares	1.66
6,000	200	93 out of 200 applicants to receive	
		200 H Shares	1.55
7,000	98	51 out of 98 applicants to receive 200	
		H Shares	1.49
8,000	123	69 out of 123 applicants to receive	
		200 H Shares	1.40
9,000	106	64 out of 106 applicants to receive	
		200 H Shares	1.34
10,000	364	236 out of 364 applicants to receive	
		200 H Shares	1.30
12,000	139	102 out of 139 applicants to receive	
		200 H Shares	1.22
14,000	93	75 out of 93 applicants to receive 200	
		H Shares	1.15
16,000	93	82 out of 93 applicants to receive 200	
		H Shares	1.10
18,000	74	71 out of 74 applicants to receive 200	
		H Shares	1.07
20,000	468	200 H Shares	1.00

20.000	221	200 H Cl 1 72 (6.221	
30,000	221	200 H Shares plus 72 out of 221	
		applicants to receive an additional 200	
		H Shares	0.88%
40,000	156	200 H Shares plus 94 out of 156	
		applicants to receive an additional 200	
		H Shares	0.80%
50,000	170	200 H Shares plus 145 out of 170	
		applicants to receive an additional 200	
		Ĥ Shares	0.74%
60,000	98	400 H Shares	0.67%
70,000	57	400 H Shares plus 18 out of 57	
		applicants to receive an additional 200	
		H Shares	0.66%
80,000	52	400 H Shares plus 27 out of 52	
		applicants to receive an additional 200	
		H Shares	0.63%
90,000	30	400 H Shares plus 22 out of 30	0.0270
20,000	50	applicants to receive an additional 200	
		H Shares	0.61%
100,000	108	400 H Shares plus 99 out of 108	0.0170
100,000	100	applicants to receive an additional 200	
		H Shares	0.58%
120,000	23		
		600 H Shares	0.50%
140,000	19	600 H Shares plus 7 out of 19	
		applicants to receive an additional 200	0.400/
		H Shares	0.48%
160,000	35	600 H Shares plus 27 out of 35	
		applicants to receive an additional 200	
		H Shares	0.47%
180,000	21	800 H Shares	0.44%
200,000	77	800 H Shares plus 24 out of 77	
		applicants to receive an additional 200	
		Ĥ Shares	0.43%
Tetal	14,312	Total number of Pool A successful	
Total	,	applicants: 4,024	

Pool B

P001 B					
			APPROXIMATE		
			PERCENTAGE ALLOTTED		
NO. OF H SHARES APPLIED	NO. OF VALID		OF THE TOTAL NO. OF H		
FOR	APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	SHARES APPLIED FOR		
		4,000 H Shares plus 124 out of 135			
		applicants to receive an additional 200			
300,000	135	H Shares	1.39%		
400,000	23	5,200 H Shares	1.30%		
500,000	10	6,200 H Shares	1.24%		
602,400	45	7,200 H Shares	1.20%		
Total	213	Total number of Pool B successful applicants: 213			

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

OTHERS / ADDITIONAL INFORMATION

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a waiver and consent under Rule 9.09(b) and Rule 10.04 of the Listing Rules and Paragraph 5(2) of the Placing Guidelines allow JianXin Medical Technology Limited (健鑫醫藥科技有限公司) (core connected person (as defined under the Listing Rules) of the Company and a close associate of Taizhou Jianxin, an existing Shareholder of the Company) and Huadong Medicine Investment Holding (Hong Kong) Limited (華東醫藥投資控股(香港)有限公司) (core connected person (as defined under the Listing Rules) of the Company and a close associate of Zhongmei Huadong, an existing Shareholder of the Company) to subscribe for H Shares as Cornerstone Investors in the Global Offering. For the details, please refer to the section headed "Waivers from Strict Compliance with the Requirements Under the Listing Rules and Exemption from the Companies (Winding Up and Miscellaneous Provisions) Ordinance – Cornerstone Subscription by Core Connected Persons during the Listing Application Process"

Each of the Directors, the Sole Sponsor and Overall Coordinators confirms that the reallocation of 936,000 Offer Shares from the International Offering to the Hong Kong Public Offering, which results the total number of the Offer Shares available under the Hong Kong Public Offering was increased to 2,140,800 Offer Shares, representing approximately 17.77% of the number of the Offer Shares initially available under the Global Offering, is in compliance with the restrictions set forth under paragraphs 8 and 9 of the Chapter 4.14 of the Guide For New Listing Applicants.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in

compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 12 March 2024 issued by Qyuns Therapeutics Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed "Underwriting – Underwriting Arrangements and Expenses – The Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on 20 March 2024).

PUBLIC FLOAT

Immediately after completion of the Global Offering, (i) taking into account the Conversion of 192,702,800 Unlisted Shares into H Shares to be issued and held by the Pre-IPO Investors and existing Shareholders, 70,392,000 H Shares, representing 31.70% of the total issued Shares will be held in the public hands, satisfying the minimum percentage requirement under Rule 8.08(1) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than 50% of the Shares held in the public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iii) there will be at least 300 Shareholders at the time of Listing in compliance with Rules 8.08(2) of the Listing Rules.

The Directors confirm that immediately after the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company; and (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, 20 March 2024, provided that the Global Offering has become unconditional and the right of termination described in "Underwriting — Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination" has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of share certificates or prior to the share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. on Wednesday, 20 March 2024, (Hong Kong time), it is expected that dealings in our H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, 20 March 2024 (Hong Kong time). The H Shares will be traded in board lots of 200 H Shares each, and the stock code of the H Shares will be 2509.

By order of the Board Qyuns Therapeutics Co., Ltd. Mr. Qiu Jiwan Chairman of the Board and Executive Director

Hong Kong, 19 March 2024

As of the date of this announcement, the executive Directors are Mr. Qiu Jiwan, Mr. Wu Yiliang and Mr. Lin Weidong, the non-executive Directors are Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu, and independent non-executive Directors are Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony.